Document is current
Any future updates will be listed below
-
Authors
Boman, Caroline
Liu, Xingrong
Eriksson Bergman, Louise
Sun, Wenwen
Tranchell, Christian
Toli, Maria Angeliki
Acs, Balazs https://orcid.org/0000-0002-0972-4633
Bergh, Jonas https://orcid.org/0000-0001-5526-1847
Foukakis, Theodoros https://orcid.org/0000-0001-8952-9987
Matikas, Alexios https://orcid.org/0000-0002-4122-9624
- License Information
-
More Information
Article History
Received: 25 March 2024
Revised: 17 June 2024
Accepted: 19 June 2024
First Online: 28 June 2024
Competing interests
: Alexios Matikas: speaker/consultancy (no personal fees) to Veracyte, Roche, Seagen; research funding paid to institution by Merck, AstraZeneca, Novartis, Veracyte, all unrelated to the current work. Jonas Bergh: research funding to institution from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche and Sanofi; honoraria from UpToDate paid to Asklepios Medicin HB; head of advisory board and stockholder at Stratipath AB. Theodoros Foukakis: institutional fees for consultancy to AstraZeneca, Gilead and Roche; personal fees for consultancy to Affibody, Pfizer, Novartis, Veracyte, Exact Sciences; honoraria from UpToDate; research funding to institution from Pfizer, AstraZeneca, Novartis and Veracyte. All the other authors had no potential conflicts of interest to disclose.
: This study was approved by the ethics review committee in Stockholm (2016/1303-31 with amendments 2018/1049-32, 2021-01147 and 2023-02918-02). The ethical approval granted a waiver for informed consent in this non-interventional collection and analysis of data from registries and patient records. This study was performed in accordance with the Declaration of Helsinki and its amendments.
